Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis
Open Access
- 25 May 2007
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (6) , 1846-1853
- https://doi.org/10.1002/art.22589
Abstract
Objective In prospective studies, only baseline radiographic damage has been identified as an independent predictor of radiographic progression in ankylosing spondylitis (AS). Several biomarkers have been identified as independent predictors of radiographic progression in rheumatoid arthritis, however, and these may be of use in AS. This study was undertaken to analyze serologic biomarkers as predictors of radiographic progression in AS. Methods We measured a panel of biomarkers reflecting cartilage turnover and osteoclasis. These biomarkers were cartilage oligomeric matrix protein, human cartilage gp-39 (YKL-40), type II collagen epitopes detected by the C2C and C1,2C degradation assays and the CPII synthesis assay, aggrecan 846 epitope, osteoprotegerin, and matrix metalloproteinase 3 (MMP-3). The analysis was performed in a cohort of AS patients from the Netherlands, Belgium, and France enrolled in a longitudinal study, the Outcome Assessments in Ankylosing Spondylitis International Study. We examined 2-year radiographic progression data scored using the modified Stoke AS Spine Score (mSASSS). Results Complete data were available on 97 patients. Only the biomarkers YKL-40 and MMP-3 showed weak to moderate univariate correlation with 2-year progression. After adjustment for sex, age, disease duration, C-reactive protein level, and baseline mSASSS, only MMP-3 was significantly associated with 2-year progression (β = 0.29, P = 0.004). Logistic regression analysis revealed MMP-3 (cutoff 68 ng/ml; odds ratio 9.4 [95% confidence interval 1.6–56]) and baseline mSASSS (cutoff 10 mSASSS units; odds ratio 18.6 [95% confidence interval 2.5–138]) as the only independent predictors of 2-year progression (cutoff 3 mSASSS units; model R2 = 50%). MMP-3 was primarily contributory in patients who already had substantial baseline damage (>10 mSASSS units). Conclusion These results indicate that MMP-3 is a significant independent predictor of radiographic progression in patients with AS, particularly in those with preexisting radiographic damage.Keywords
This publication has 30 references indexed in Scilit:
- Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosisArthritis Research & Therapy, 2006
- Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysisAnnals of the Rheumatic Diseases, 2006
- Association of higher levels of serum cartilage oligomeric matrix protein and N‐telopeptide crosslinks with the development of radiographic hip osteoarthritis in elderly womenArthritis & Rheumatism, 2005
- How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured?Arthritis & Rheumatism, 2005
- Urinary type II collagen helical peptide (HELIX‐II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritisArthritis & Rheumatism, 2005
- Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring systemAnnals of the Rheumatic Diseases, 2005
- What is the most appropriate radiologic scoring method for ankylosing spondylitis?Arthritis & Rheumatism, 2004
- Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis.Osteoarthritis and Cartilage, 2004
- Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 yearsAnnals of the Rheumatic Diseases, 2004
- Markers for type II collagen breakdown predict the effect of disease‐modifying treatment on long‐term radiographic progression in patients with rheumatoid arthritisArthritis & Rheumatism, 2004